Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denintuzumab Mafodotin + RICE vs RICE in Relapsed/Refractory DLBCL
NCT02592876Phase 2Terminated
- Sponsor
- Seagen Inc.
- Start
- Oct 2015
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of denintuzumab mafodotin in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Seagen Inc.. Started Oct 2015; status: terminated.
02
Drugs
denintuzumab mafodotin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02592876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592876.